Company Update (NYSE:BAX): Full Data on Baxter’s Investigational Recombinant Treatment BAX 111 Supports Potential Role to Treat von Willebrand Disease
April 17, 2015 at 16:30 PM EDT
[Business Wire] – Baxter International Inc. today presented additional data from the Phase III clinical trial of BAX 111, the first highly-purified recombinant von Willebrand Factor in clinical development as a treatment for . . . → Read More: Company Update (NYSE:BAX): Full Data on Baxter’s Investigational Recombinant Treatment BAX 111 Supports Potential Role to Treat von Willebrand Disease Similar Articles: Stock Update (NYSE:BAX): Coherus BioSciences and Baxter Announce Amendment to Etanercept Biosimilar Collaboration Agreement Company Update (NYSE:BAX): Baxter Expands Access to Healthcare Through Collaborations and Charitable Giving Market Update (NYSE:BAX): Baxter’s BioScience Business Acquires Biopharmaceutical Company SuppreMol